BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity With Manageable Tolerability Among Heavily Pretreated Patients With Squamous Cell Carcinoma Of The Head And Neck At The 2024 ESMO Annual Meeting
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity With Manageable Tolerability Among Heavily Pretreated Patients With Squamous Cell Carcinoma Of The Head And Neck At The 2024 ESMO Annual Meeting
An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens
在兩種給藥方案中取得了32%的整體反應率（ORR）的持續性完全緩解（CR）
Underscores ozuriftamab vedotin's activity in a high unmet need SCCHN patient population
強調了ozuriftamab vedotin在高度未滿足需求的SCCHN患者人群中的活性
The conditionally binding ADC targeting ROR2 was notably well tolerated
有條件結合的ADC靶向ROR2表現出顯著的耐受性
The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024
公司打算在2024年下半年與FDA會面，討論SCCHN潛在的註冊試驗
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented a poster of promising Phase 2 trial data at the European Society for Medical Oncology (ESMO) Annual Meeting. The poster presentation entitled, "Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck," reported multiple confirmed responses among heavily pretreated patients who tolerated treatment well. The Company's novel, conditionally active anti-ROR2-ADC was recently granted FDA Fast Track Designation for treatment of patients with recurrent or metastatic (R/M) SCCHN.
2024年9月16日，加利福尼亞州聖地亞哥（GLOBE NEWSWIRE）-- BioAtla，Inc.（納斯達克：BCAB）,一家全球臨床階段的生物技術公司，專注於開發用於固性腫瘤治療的有條件活性生物製品（CAB）抗體治療藥物，今天在歐洲醫學腫瘤學年會（ESMO）上展示了一項有前途的2期試驗數據的海報。這個名爲“ozuriftamab vedotin（BA3021）的有條件活性生物（CAB）-ROR2-ADC的2期試驗，在複發性或轉移性頭頸部鱗狀細胞癌患者中報告了多個確認的反應，這些患者對治療有很好的耐受性。公司的新型，有條件活性的抗-ROR2-ADC最近被FDA授予了用於治療復發或轉移性（R/M）SCCHN患者的快速通道認定。
譯文內容由第三人軟體翻譯。
